Agenus Inc.

Memorial Sloan Kettering Cancer Center

Ludwig Institute for Cancer Research Limited

Yale University

Satori Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

Mark Arthur Findeis

Nicholas Stuart Wilson

David Adam Savitsky

Cornelia Anne Mundt

Marc A Van Dijk

Dennis John Underwood

Gerd J Ritter

Taha Merghoub

Jedd David Wolchok

David Schaer

Jean-Marie Cuillerot

Igor Proscurshim

Olga Shebanova

Sankar Ghosh

Kathryn Phillips

Michael J May

Benjamin Maxime Morin

Gerhard Hannig

Olga Ignatovich

Yanping Xiao

Dhan Sidhartha Chand

Frank Clemens Schroeder

Kollol Pal

Roberta Zappasodi

Rikke Baek Holmgaard

Bishnu Joshi

Marc Van Dijk

ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF

The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CTLA-4 antibodies and methods of use thereof

Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.

Antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD137 antibodies and methods of use thereof

Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.

Heat shock protein-binding peptide compositions and methods of use thereof

As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Synthesis of compounds useful as modulators of amyloid-beta production

The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-&#x3ba;B-dependent target gene expression in a cell.

Anti-inflammatory compounds and uses thereof

As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Compounds useful for treating neurodegenerative disorders

Growing community of inventors

Belmont, MA, United States of America

Mark Arthur Findeis